Current Strategy Viewpoints - The capital market experienced fluctuations in early February but rebounded later in the month, primarily due to reduced trading activity before the Spring Festival and short-term policy guidance [1] - The market is expected to enter a phase of economic data and policy verification, with a seasonal increase in trading activity post-Spring Festival, laying a foundation for future market performance [1] - Upcoming economic and corporate profit data, along with the National People's Congress in March, will be crucial for setting the annual policy tone and economic targets, which are significant for the capital market [1] Sector Focus - Short-term focus on safe-haven assets and resource products due to tensions in the Middle East, including precious metals and oil sectors [2] - Long-term focus on growth and cyclical sectors, with particular attention to small-cap stocks that typically perform well in spring [2] - Key sectors to watch include humanoid robots, computing, and AI, benefiting from sustained industry enthusiasm and increased risk appetite among investors [2] Macro Overview - The upcoming National People's Congress will set the tone for the annual economy, with GDP growth targets expected to be set between 4.5% and 5% [8] - Fiscal policy is anticipated to include a deficit rate of 4.0% and new special bonds totaling 5 trillion yuan, indicating a significant increase in fiscal deficit compared to last year [8] Financial Engineering - The A-share market has seen a rise in industry crowding, particularly in media and resource sectors, with the media sector showing a crowding degree of 98.25% [12][14] - The resource sector continues to perform well, with price fluctuations leading to a decrease in crowding indicators, suggesting a potential for continued upward movement [13] Electronic Communication Industry - The upcoming GTC conference is expected to showcase new chip developments from NVIDIA, reinforcing AI as a core investment theme [24] - The demand for storage products is projected to rise significantly, driven by strong AI customer needs and price increases in the DRAM market [25] Computer Industry - The rapid iteration of domestic AI large models is expected to drive significant growth in computing power investments, with a focus on world model technology advancements [28] - The demand for AI-driven applications is anticipated to increase, leading to a surge in computing needs and infrastructure investments [29] New Energy Industry - Focus on hydrogen and ammonia projects, with government support for integrated energy bases expected to drive growth in this sector [32] - The electric power equipment sector is poised for growth due to ongoing global energy demands and potential easing of import restrictions in India [32] High-end Manufacturing Industry - The humanoid robot sector is entering a phase of mass production, with significant advancements showcased during the Spring Festival [35] - The North American AI supply chain remains robust, with ongoing demand for advanced equipment and materials expected to drive growth [36]

证券之星消息，2月27日南向资金减持13.41万股微创医疗（00853.HK）。近5个交易日中，获南向资金 增持的有3天，累计净增持168.96万股。近20个交易日中，获南向资金增持的有14天，累计净增持 1470.22万股。截至目前，南向资金持有微创医疗（00853.HK）9.26亿股，占公司已发行普通股的 48.28%。 微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

微创医疗(00853)公布心脉医疗(688016.SH)2025年年度业绩快报，营业总收入约13.51亿元，同比增长 11.96%;归属于母公司所有者的净利润约5.63亿元，同比增长12.17%;基本每股收益4.65元。 公司新增多款创新产品在国内获批上市，包括Cratos分支型主动脉覆膜支架系统、经颈静脉肝内穿刺套 件、聚乙烯醇栓塞微球。公司累计23款产品获得NMPA首次注册证，11款产品在28个海外市场获得首次 注册证;累计获得海外产品注册证110余张，其中6款产品获得CE认证，3款产品获得欧盟定制证书。 除上述产品外，公司在研产品稳步推进，管线丰富，其中Aegis II腹主动脉覆膜支架系统完成注册资料 递交;Hector胸主多分支覆膜支架系统已进入国内上市前多中心临床阶段，且于报告期内进入国家创 新"绿色通道"，并已通过欧盟定制方式实现商业化，同时该产品美国Breakthrough Device Designation申 请已提交FDA;胸腹主动脉覆膜支架系统(定制)已获得国内备案证;髂动脉分支覆膜支架系统即将进入临 床试验启动阶段。外周业务方面，外周介入微导管、可解脱带纤维毛栓塞弹簧圈、机械血栓切除导 ...

公司新增多款创新产品在国内获批上市，包括 Cratos 分支型主动脉覆膜支架系统、经颈静脉肝内穿刺 套件、聚乙烯醇栓塞微球。公司累计 23 款产品获得 NMPA 首次注册证，11 款产品在 28 个海外市场获 得首次注册证;累计获得海外产品注册证 110 余张，其中 6 款产品获得 CE 认证，3 款产品获得欧盟定制 证书。 除上述产品外，公司在研产品稳步推进，管线丰富，其中 Aegis II 腹主动脉覆膜支架系统完成注册资料 递交;Hector 胸主多分支覆膜支架系统已进入国内上市前多中心临床阶段，且于报告期内进入国家创 新"绿色通道"，并已通过欧盟定制方式实现商业化，同时该产品美国 Breakthrough Device Designation 申请已提交 FDA;胸腹主动脉覆膜支架系统(定制)已获得国内备案证;髂动脉分支覆膜支架系统即将进入 临床试验启动阶段。外周业务方面，外周介入微导管、可解脱带纤维毛栓塞弹簧圈、机械血栓切除导 管、新一代外周裸球囊导管预计 2026 年获批上市;膝下药物球囊扩张导管、TIPS 覆膜支架系统已完成 注册递交;外周血管药物洗脱支架系统处于临床植入阶段。同时，公司创新产品的 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 1 股東及投資者請注意，以上財務資料根據中國會計準則編製，並僅與心脈醫療科技的業務有關，而 與本集團其他附屬公司無關。該等資料未經審核，且(a)並未撇除集團內交易，(b)並不包括本集團所 有業務，及(c)並不代表或全面反映本集團業務或狀況。 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 微創醫療科學有限公司* 上海微創心脈醫療科技（集團）股份有限公司 截至二零二五年十二月三十一日止十二個月未經審核財務資料 以下所載為上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）截至二零二五年十二月 三十一日止十二個月的未經審核財務資料。本公司持有心脈醫療科技40.32%的股權，其業績於本公 司財務報表合併入賬。心脈醫療科技的股份在上海證券交易所科創板上市。 | | 截至 | 截至 | | | --- | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 微創醫療科學有限公司* （於開曼群島註冊成立的有限公司） （股份代號：00853） 海外監管公告 常兆華博士 主席 本海外監管公告乃根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.10B條刊 發。 請參閱隨附上海微創心脈醫療科技（集團）股份有限公司（「心脈醫療科技」）於上海證券交易所科創板 （「科創板」）刊發之公告（「該公告」），內容有關其二零二五年年度業績快報公告。 心脈醫療科技為一家於科創板上市之公司。於本公告日期，本公司持有心脈醫療科技已發行股本約 40.32%及其業績於本公司財務報表合併入賬。 於聯交所網站登載該公告，僅為向香港投資者進行同等的資訊傳達及遵守上市規則第13.10B條，別 無其他目的。 承董事會命 中國上海，二零二六年二月二十七日 於本公告日期，本公司之執行董事為常兆華博士；本公司之非執行董事為谷峰博士、門慶兵博士及 孫維琴女士；及本公司之獨立非執行董事為 ...

微创医疗科学有限公司是一家主要从事医疗器械的销售、生产、研究及开发（R&D）的投资控股公 司。该公司通过八个分部开展业务。心血管介入业务分部包括植入器械、通路器械等产品。骨科医疗器 械业务分部包括关节重建、脊柱等器械。心律管理（CRM）业务分部包括起搏器、除颤器等器械。大 动脉及外周血管介入业务分部包括"L-REBOA"主动脉阻断球囊等产品。神经介入业务分部包括脑动脉 粥样硬化狭窄、弹簧圈等产品。结构性心脏病业务分部包括经导管主动脉瓣植入术等产品。手术机器人 业务分部从事手术机器人器械的制造及研发。外科医疗器械业务分部从事外科医疗器械的制造及研发。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，2月26日南向资金增持161.11万股微创医疗（00853.HK）。近5个交易日中，获南向资金 增持的有4天，累计净增持242.47万股。近20个交易日中，获南向资金增持的有15天，累计净增持1842.8 万股。截至目前，南向资金持有微创医疗（00853.HK）9.26亿股，占公司已发行普通股的48.28%。 ...

《破界·领航：全球视野下的中国医械创新白皮书》是一份专为医疗器械经销商/代理商/企业量身打造的创新导航图。我们以全球视野+本土洞察，深度剖 析市场，致力于成为您发掘高潜力创新产品、规避风险、制定市场策略的权威决策参考。 四大核心价值 赋能经销商决策！ 01 打破信息壁垒！ * 聚焦心血管介入、手术机器人、医学影像、肿瘤消融、骨科、内窥镜、新型医用材料等16个高增长热门赛道。 *精选72款国内外具有代表性的创新医疗器械产品，从政策支持、市场前景、核心技术、临床应用、竞争格局、厂家实力进行全方位、多维度深度剖析。 * 打破信息壁垒、减少信息不对称，帮助医疗器械经销商，深度且全面地了解目前市面上的创新医疗器械产品。 白皮书部分目录页展示 深度拆解16大赛道72+标杆案例 03 政策先行, 国产创新医械"黄金时代"来临 | 2、高端化:首创性技术多赛道开花 | ... | | --- | --- | | 3、智能化:"人工智能+"应用广泛触及 | 1 | | 4、本土化:外企本土化布局进阶提速 | 4 | | 5、精准化:迈向精准化大势所趋 | 5 | 02 赛道纵观, 创新医械细分领域趋势详解 | 1、IVD:从新 ...

Core Viewpoint - Southbound funds increased their holdings in MicroPort Scientific Corporation (00853.HK) by 242,100 shares on February 23, indicating a positive sentiment towards the company despite some fluctuations in the previous trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, there were 2 days of net reductions in holdings by southbound funds, totaling a net decrease of 915,800 shares [1] - Over the past 20 trading days, southbound funds increased their holdings on 15 days, with a cumulative net increase of 16,929,900 shares [1] - Currently, southbound funds hold 924 million shares of MicroPort, accounting for 48.21% of the company's total issued ordinary shares [1] Group 2: Company Overview - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1] - Key products include implantable devices, surgical robots, and various instruments for cardiovascular and orthopedic applications [1]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 1.4415 million shares on February 13, with net increases recorded on 4 out of the last 5 trading days, totaling 676,500 shares [1] - Over the past 20 trading days, there have been net increases on 15 days, amounting to 20.3817 million shares [1] - Currently, southbound funds hold 926 million shares of MicroPort Medical, representing 48.26% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal devices [1] - Cardiac Rhythm Management (CRM): Includes pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Features products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Involves products for carotid artery atherosclerosis and coils [1] - Structural Heart Disease Business: Engages in transcatheter aortic valve implantation [1] - Surgical Robotics Business: Manufactures and develops surgical robotic devices [1] - Surgical Medical Devices Business: Focuses on the manufacturing and R&D of surgical medical devices [1]